{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:07:57Z","timestamp":1790179677947,"version":"4.1.0"},"reference-count":35,"publisher":"American Chemical Society (ACS)","issue":"25","license":[{"start":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T00:00:00Z","timestamp":1681171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30 CA08748"],"award-info":[{"award-number":["P30 CA08748"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["R35 CA232130"],"award-info":[{"award-number":["R35 CA232130"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,6,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multiple myeloma (MM) is the second most prevalent hematological malignancy. It remains incurable despite the availability of novel therapeutic approaches, marking an urgent need for new agents for noninvasive targeted imaging of MM lesions. CD38 has proven to be an excellent biomarker due to its high expression in aberrant lymphoid and myeloid cells relative to normal cell populations. Using isatuximab (Sanofi), the latest FDA-approved CD38-targeting antibody, we have developed Zirconium-89\u00ad(89Zr)-labeled isatuximab as a novel immunoPET tracer for the in vivo delineation of MM and evaluated the extension of its applicability to lymphomas. In vitro studies validated the high binding affinity and specificity of 89Zr-DFO-isatuximab for CD38. PET imaging demonstrated the high performance of 89Zr-DFO-isatuximab as a targeted imaging agent to delineate tumor burden in disseminated models of MM and Burkitt\u2019s lymphoma. Ex vivo biodistribution studies confirmed that high accumulations of the tracer in bone marrow and bone skeleton correspond to specific disease lesions as they are reduced to background in blocking and healthy controls. This work demonstrates the promise of 89Zr-DFO-isatuximab as an immunoPET tracer for CD38-targeted imaging of MM and certain lymphomas. More importantly, its potential as an alternative to 89Zr-DFO-daratumumab holds great clinical relevance.<\/jats:p>","DOI":"10.1021\/acsomega.3c00624","type":"journal-article","created":{"date-parts":[[2023,4,11]],"date-time":"2023-04-11T10:47:31Z","timestamp":1681210051000},"page":"22486-22495","source":"Crossref","is-referenced-by-count":15,"title":["89Zr-DFO-Isatuximab for CD38-Targeted ImmunoPET\nImaging of Multiple Myeloma and Lymphomas"],"prefix":"10.1021","volume":"8","author":[{"given":"Natalia","family":"Herrero Alvarez","sequence":"first","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , , , ,","place":["New York, New York, United States, 10065"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexa L.","family":"Michel","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , , , ,","place":["New York, New York, United States, 10065"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tara D.","family":"Viray","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , , , ,","place":["New York, New York, United States, 10065"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marius E.","family":"Mayerhoefer","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , , , ,","place":["New York, New York, United States, 10065"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7065-4534","authenticated-orcid":true,"given":"Jason S.","family":"Lewis","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center , , , ,","place":["New York, New York, United States, 10065"]},{"name":"Weill Cornell Medicine , , , ,","place":["New York, New York, United\nStates, 10065"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"316","published-online":{"date-parts":[[2023,4,11]]},"reference":[{"issue":"1","key":"2026081707203915600_cit1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","article-title":"Cancer statistics,\n2022","volume":"72","author":"Siegel","year":"2022","journal-title":"CA: A Cancer Journal for Clinicians"},{"issue":"6","key":"2026081707203915600_cit2","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1053\/j.seminoncol.2016.11.004","article-title":"Multiple myeloma\nepidemiology and survival: A unique malignancy","volume":"43","author":"Kazandjian","year":"2016","journal-title":"Seminars in Oncology"},{"key":"2026081707203915600_cit3","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/978-3-319-40320-5_1","article-title":"MGUS and Smoldering\nMultiple Myeloma: Diagnosis and\nEpidemiology","volume":"169","author":"Mateos","year":"2016","journal-title":"Cancer Treat Res."},{"issue":"2","key":"2026081707203915600_cit4","doi-asserted-by":"publisher","first-page":"287","DOI":"10.7150\/thno.14400","article-title":"New Perspectives Offered by Nuclear\nMedicine for the Imaging and Therapy of Multiple Myeloma","volume":"6","author":"Mesguich","year":"2016","journal-title":"Theranostics"},{"issue":"1","key":"2026081707203915600_cit5","doi-asserted-by":"publisher","first-page":"134","DOI":"10.3390\/molecules25010134","article-title":"Positron Emission Tomography\n(PET) Radiopharmaceuticals in Multiple Myeloma","volume":"25","author":"Sachpekidis","year":"2020","journal-title":"Molecules"},{"key":"2026081707203915600_cit6","doi-asserted-by":"publisher","first-page":"1187","DOI":"10.3389\/fimmu.2019.01187","article-title":"The Multi-faceted Ecto-enzyme CD38:\nRoles in Immunomodulation, Cancer, Aging, and Metabolic Diseases","volume":"10","author":"Hogan","year":"2019","journal-title":"Frontiers in Immunology"},{"issue":"4","key":"2026081707203915600_cit7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1016\/j.tips.2018.02.001","article-title":"The Pharmacology of CD38\/NADase: An Emerging Target\nin Cancer and Diseases of Aging","volume":"39","author":"Chini","year":"2018","journal-title":"Trends Pharmacol.\nSci."},{"issue":"1","key":"2026081707203915600_cit8","doi-asserted-by":"publisher","first-page":"101148","DOI":"10.1016\/j.beha.2020.101148","article-title":"Current and potential applications\nof positron emission\ntomography for multiple myeloma and plasma cell disorders","volume":"33","author":"Ulaner","year":"2020","journal-title":"Best Practice & Research Clinical Haematology"},{"issue":"SEP","key":"2026081707203915600_cit9","doi-asserted-by":"publisher","first-page":"2134","DOI":"10.3389\/fimmu.2018.02134","article-title":"CD38 antibodies in multiple myeloma:\nMechanisms of action and modes of resistance","volume":"9","author":"van\nde Donk","year":"2018","journal-title":"Frontiers in Immunology"},{"issue":"14","key":"2026081707203915600_cit10","doi-asserted-by":"publisher","first-page":"2364","DOI":"10.1002\/cncr.32065","article-title":"Daratumumab in multiple\nmyeloma","volume":"125","author":"Nooka","year":"2019","journal-title":"Cancer"},{"issue":"2","key":"2026081707203915600_cit11","doi-asserted-by":"publisher","first-page":"216","DOI":"10.2967\/jnumed.117.196063","article-title":"Preclinical\nDevelopment of CD38-Targeted [89Zr]\u00adZr-DFO-Daratumumab for Imaging\nMultiple Myeloma","volume":"59","author":"Ghai","year":"2018","journal-title":"J. Nucl. Med."},{"issue":"3","key":"2026081707203915600_cit12","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1148\/radiol.2020192621","article-title":"CD38-targeted Immuno-PET\nof Multiple Myeloma: From Xenograft Models to First-in-Human Imaging","volume":"295","author":"Ulaner","year":"2020","journal-title":"Radiology"},{"issue":"9","key":"2026081707203915600_cit13","doi-asserted-by":"publisher","first-page":"2721","DOI":"10.3390\/cancers12092721","article-title":"Targeted-Alpha-Therapy\nCombining Astatine-211 and anti-CD138\nAntibody in A Preclinical Syngeneic Mouse Model of Multiple Myeloma\nMinimal Residual Disease","volume":"12","author":"Gouard","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"8","key":"2026081707203915600_cit14","doi-asserted-by":"publisher","first-page":"e1607673","DOI":"10.1080\/2162402X.2019.1607673","article-title":"Daratumumab-225Actinium\nconjugate demonstrates greatly enhanced antitumor activity against\nexperimental multiple myeloma tumors","volume":"8","author":"Dawicki","year":"2019","journal-title":"OncoImmunology"},{"issue":"2","key":"2026081707203915600_cit15","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11307-020-01542-4","article-title":"Preclinical\nDevelopment of Near-Infrared-Labeled CD38-Targeted\nDaratumumab for Optical Imaging of CD38 in Multiple Myeloma","volume":"23","author":"Cho","year":"2021","journal-title":"Mol. Imaging Biol."},{"issue":"1","key":"2026081707203915600_cit16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3390\/cells9010167","article-title":"Mechanisms\nof Resistance to Anti-CD38 Daratumumab in Multiple Myeloma","volume":"9","author":"Saltarella","year":"2020","journal-title":"Cells"},{"key":"2026081707203915600_cit17","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2020.38.15_suppl.e20547","article-title":"Investigating macrophage\nfunction as a mechanism of resistance to daratumumab in relapsed refractory\nmultiple myeloma patients","volume":"38","author":"Kambhampati","year":"2020","journal-title":"Journal of Clinical\nOncology"},{"issue":"1","key":"2026081707203915600_cit18","doi-asserted-by":"publisher","first-page":"99","DOI":"10.2119\/molmed.2013.00009","article-title":"Anti-CD38 antibody\ntherapy: windows of opportunity yielded by the functional characteristics\nof the target molecule","volume":"19","author":"Chillemi","year":"2013","journal-title":"Mol. Med."},{"issue":"3","key":"2026081707203915600_cit19","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","article-title":"Daratumumab\ndepletes CD38+ immune regulatory\ncells, promotes T-cell expansion, and skews T-cell repertoire in multiple\nmyeloma","volume":"128","author":"Krejcik","year":"2016","journal-title":"Blood"},{"key":"2026081707203915600_cit20","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1182\/blood.V130.Suppl_1.123.123","article-title":"Single Cell Resolution\nProfiling Defines the Innate\nand Adaptive Immune Repertoires Modulated By Daratumumab and IMiDs\nTreatment in Multiple Myeloma (MM)","volume":"130","author":"Neri","year":"2017","journal-title":"Blood"},{"issue":"7","key":"2026081707203915600_cit21","doi-asserted-by":"publisher","first-page":"959","DOI":"10.1182\/blood-2016-03-703439","article-title":"CD38\nexpression and\ncomplement inhibitors affect response and resistance to daratumumab\ntherapy in myeloma","volume":"128","author":"Nijhof","year":"2016","journal-title":"Blood"},{"issue":"12","key":"2026081707203915600_cit22","doi-asserted-by":"publisher","first-page":"3526","DOI":"10.1038\/s41375-021-01262-w","article-title":"Final results of a phase\n1b study of isatuximab short-duration fixed-volume infusion combination\ntherapy for relapsed\/refractory multiple myeloma","volume":"35","author":"Usmani","year":"2021","journal-title":"Leukemia"},{"issue":"5","key":"2026081707203915600_cit23","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","article-title":"A phase 2 study of isatuximab monotherapy in\npatients\nwith multiple myeloma who are refractory to daratumumab","volume":"11","author":"Mikhael","year":"2021","journal-title":"Blood Cancer J."},{"issue":"17","key":"2026081707203915600_cit24","doi-asserted-by":"publisher","first-page":"4574","DOI":"10.1158\/1078-0432.CCR-14-0695","article-title":"SAR650984, A Novel Humanized\nCD38-Targeting Antibody, Demonstrates Potent Antitumor Activity in\nModels of Multiple Myeloma and Other CD38+ Hematologic\nMalignancies","volume":"20","author":"Deckert","year":"2014","journal-title":"Clin. Cancer Res."},{"issue":"12","key":"2026081707203915600_cit25","doi-asserted-by":"publisher","first-page":"1522","DOI":"10.3390\/cells8121522","article-title":"Therapeutic Opportunities with Pharmacological\nInhibition of CD38 with Isatuximab","volume":"8","author":"Martin","year":"2019","journal-title":"Cells"},{"issue":"7","key":"2026081707203915600_cit26","doi-asserted-by":"publisher","first-page":"2004","DOI":"10.3324\/haematol.2020.268656","article-title":"Comparison\nof CD38 antibodies in vitro and ex vivo\nmechanisms of action in multiple myeloma","volume":"106","author":"Kinder","year":"2021","journal-title":"Haematologica"},{"key":"2026081707203915600_cit27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.bbrc.2020.12.048","article-title":"Crystal\nstructure of CD38 in complex with daratumumab, a first-in-class anti-CD38\nantibody drug for treating multiple myeloma","volume":"536","author":"Lee","year":"2021","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"5","key":"2026081707203915600_cit28","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41408-021-00478-4","article-title":"A phase 2 study of isatuximab monotherapy in\npatients\nwith multiple myeloma who are refractory to daratumumab","volume":"11","author":"Mikhael","year":"2021","journal-title":"Blood Cancer Journal"},{"issue":"10","key":"2026081707203915600_cit29","doi-asserted-by":"publisher","first-page":"3176","DOI":"10.1158\/1078-0432.CCR-18-1597","article-title":"The Mechanism of Action\nof the Anti-CD38 Monoclonal\nAntibody Isatuximab in Multiple Myeloma","volume":"25","author":"Moreno","year":"2019","journal-title":"Clin.\nCancer Res."},{"issue":"12","key":"2026081707203915600_cit30","doi-asserted-by":"publisher","first-page":"1395","DOI":"10.1080\/14712598.2021.1841747","article-title":"Isatuximab\nfor the treatment of relapsed\/refractory multiple myeloma","volume":"20","author":"Richardson","year":"2020","journal-title":"Expert Opin Biol. Ther"},{"issue":"34","key":"2026081707203915600_cit31","doi-asserted-by":"publisher","first-page":"4797","DOI":"10.2217\/fon-2021-0568","article-title":"Isatuximab for relapsed\/refractory\nmultiple myeloma: review of key subgroup analyses from the Phase III\nICARIA-MM study","volume":"17","author":"Richardson","year":"2021","journal-title":"Future Oncology"},{"key":"2026081707203915600_cit32","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.nucmedbio.2019.04.005","article-title":"A rapid bead-based radioligand binding\nassay for the determination of target-binding fraction and quality\ncontrol of radiopharmaceuticals","volume":"71","author":"Sharma","year":"2019","journal-title":"Nucl. Med.\nBiol."},{"issue":"1","key":"2026081707203915600_cit33","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1182\/blood-2017-03-774422","article-title":"Low expression of hexokinase-2 is associated with false-negative\nFDG-positron emission tomography in multiple myeloma","volume":"130","author":"Rasche","year":"2017","journal-title":"Blood"},{"issue":"6","key":"2026081707203915600_cit34","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1007\/s00259-019-04312-9","article-title":"Low hexokinase-2 expression-associated\nfalse-negative (18)\u00adF-FDG PET\/CT as a potential prognostic predictor\nin patients with multiple myeloma","volume":"46","author":"Abe","year":"2019","journal-title":"Eur. J. Nucl.\nMed. Mol. Imaging"},{"issue":"3","key":"2026081707203915600_cit35","doi-asserted-by":"publisher","first-page":"348","DOI":"10.2967\/jnumed.118.217539","article-title":"Hexokinase-2 Expression in (11)\u00adC-Methionine-Positive, (18)\u00adF-FDG-Negative\nMultiple Myeloma","volume":"60","author":"Kircher","year":"2019","journal-title":"J. Nucl. Med."}],"container-title":["ACS Omega"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pubs.acs.org\/doi\/pdf\/10.1021\/acsomega.3c00624","content-type":"application\/pdf","content-version":"vor","intended-application":"unspecified"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/8\/25\/22486\/4392916\/ao3c00624.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/pubs.acs.org\/acsodf\/article-pdf\/8\/25\/22486\/4392916\/ao3c00624.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T11:28:15Z","timestamp":1786966095000},"score":1,"resource":{"primary":{"URL":"https:\/\/pubs.acs.org\/acsodf\/article\/8\/25\/22486\/407383\/89Zr-DFO-Isatuximab-for-CD38-Targeted-ImmunoPET"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,4,11]]},"references-count":35,"journal-issue":{"issue":"25","published-online":{"date-parts":[[2023,4,11]]},"published-print":{"date-parts":[[2023,6,27]]}},"URL":"https:\/\/doi.org\/10.1021\/acsomega.3c00624","relation":{},"ISSN":["2470-1343"],"issn-type":[{"value":"2470-1343","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,4,11]]}}}